Recruiting NCT04324125

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

— Observational Non Small Cell Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to: Registry conditions: Non Small Cell Lung Cancer. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: China
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Official title

Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Detailed description

Main enrolled criteria:

Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Secondary outcome measures (2)

≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
HER 2 Insertion or Amplification
First Diagnosis and Treatment
Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

China · 1 center

NCT: NCT04324125 · CRONUS